BLC2 inhibitor venetoclax was investigated in a prospective phase II trial in patients with BCL2-positive R/R PTCL after at least one previous standard line of treatment (NCT03552692). The gene discussed is BCL2; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.